» Articles » PMID: 35605741

Chronic Hepatitis E: Advancing Research and Patient Care

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2022 May 23
PMID 35605741
Authors
Affiliations
Soon will be listed here.
Abstract

The hepatitis E virus (HEV) was initially thought to exclusively cause acute hepatitis. However, the first diagnosis of chronic hepatitis E in transplant recipients in 2008 profoundly changed our understanding of this pathogen. We have now begun to understand that specific HEV genotypes can cause chronic infection in certain immunocompromised populations. Over the past decade, dedicated clinical and experimental research has substantiated knowledge on the epidemiology, transmission routes, pathophysiological mechanisms, diagnosis, clinical features and treatment of chronic HEV infection. Nevertheless, many gaps and major challenges remain, particularly regarding the translation of knowledge into disease prevention and improvement of clinical outcomes. This article aims to highlight the latest developments in the understanding and management of chronic hepatitis E. More importantly, we attempt to identify major knowledge gaps and discuss strategies for further advancing both research and patient care.

Citing Articles

Descriptive Comparative Transcriptomic Analysis of Genotype IV SHEV ORF3-Expressing HepG2 Cells.

Jiao H, Meng C, Jiao F, Zhou G, Wang L, Wu S Microorganisms. 2025; 13(2).

PMID: 40005777 PMC: 11858143. DOI: 10.3390/microorganisms13020412.


Effectiveness of a hepatitis E vaccine against medically-attended symptomatic infection in HBsAg-positive adults from a test-negative design study.

Zhuang C, Liu X, Huang X, Lu J, Zhu K, Liao M Nat Commun. 2025; 16(1):1699.

PMID: 39962038 PMC: 11832733. DOI: 10.1038/s41467-025-57021-3.


Viral hepatitis E: Clinical manifestations, treatment, and prevention.

Luo Q, Chen J, Zhang Y, Xu W, Liu Y, Xie C Liver Res. 2025; 8(1):11-21.

PMID: 39959034 PMC: 11771268. DOI: 10.1016/j.livres.2024.01.001.


Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab.

Kogias D, Gavriilidis E, Antoniadou C, Skeva A, Kafalis N, Tsilingiris D J Viral Hepat. 2025; 32(3):e70005.

PMID: 39927678 PMC: 11809126. DOI: 10.1111/jvh.70005.


Liver diseases: epidemiology, causes, trends and predictions.

Gan C, Yuan Y, Shen H, Gao J, Kong X, Che Z Signal Transduct Target Ther. 2025; 10(1):33.

PMID: 39904973 PMC: 11794951. DOI: 10.1038/s41392-024-02072-z.